Information Provided By: 
Fly News Breaks for November 6, 2015
PSDV
Nov 6, 2015 | 15:00 EDT
Northland analyst Suraj Kalia said pSividia provided important updates along with its Q1 report, identifying the announcement that the FDA agreed on an NDA filing based on a 6-month efficacy data for both Phase III trials for Medidur as "perhaps the most interesting" piece of new information. An important catalyst should be "coming up soon," with top-line data for the first trial potentially available by end of FY15, noted Kalia, who has on Outperform rating and $10 target on pSividia shares.
News For PSDV From the Last 2 Days
There are no results for your query PSDV
